Jay S. Duker, MD, is the President & CEO and Board Director of EyePoint Pharmaceuticals, a biotech company that develops sustained-release medications to treat serious ocular disorders. Dr. Duker has devoted more than 30 years to the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical research, business, and academic settings. Dr. Duker joined EyePoint in 2020. Prior to becoming President & CEO in July 2023, Dr. Duker served EyePoint as President and Chief Operating Officer, and as Chief Strategic Scientific Officer. He also served on EyePoint’s Board of Directors from 2016-2020 prior to his re-appointment to the Board of Directors in July 2023.
Between 2001 and 2021, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston, Massachusetts. He has published over 345 journal articles, concentrating on retinal imaging, retinal vascular diseases, and drug delivery to the posterior segment. Dr. Duker remains in clinical practice, seeing patients with medical retinal disorders and intraocular tumors.
Dr. Duker is the founder of three successful start-up companies; SurgiSite Boston, the fifth busiest independent ophthalmology-only out-patient surgery center in the United States, the Boston Image Reading Center (BIRC), and Hemera Biosciences, the developer of HMR59, an AAV-based gene therapy for dry age-related macular degeneration that is now in a ph2 clinical trial after being acquired by Janssen in 2020. Dr. Duker was on the Board of Sesen Bio and served as its Chair. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.